Literature DB >> 20524090

The "J curve" problem revisited: old and new findings.

Guido Grassi1, Fosca Quarti-Trevano, Raffaella Dell'Oro, Giuseppe Mancia.   

Abstract

This paper critically addresses the issue of the "J-curve" paradox--the finding described in studies performed about 30 years ago indicating that treatment-induced systolic blood pressure values below 120 or 125 mm Hg and diastolic blood pressure values below 75 mm Hg are characterized by an increase, rather than a reduction, in the incidence of coronary events. This paper focuses on four major subjects: 1) the benefits of a lower blood pressure target during treatment; 2) the historical background of the "J-curve" phenomenon; 3) the evidence collected in recent clinical trials regarding the existence of a "J-curve" in treated hypertensive patients; and 4) the recent recommendations by the Task Force Committee of the European Society of Hypertension on blood pressure goals to be achieved during treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524090     DOI: 10.1007/s11906-010-0121-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  41 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

3.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

4.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

5.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

6.  Treatment of mild hypertension: a five year controlled drug trial. The Oslo study.

Authors:  A Helgeland
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

7.  Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension.

Authors:  I M Stewart
Journal:  Lancet       Date:  1979-04-21       Impact factor: 79.321

8.  Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1982-02-05       Impact factor: 56.272

9.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

10.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

View more
  5 in total

1.  Prevention of microalbuminuria in diabetes mellitus: results of the ROADMAP trial.

Authors:  Guido Grassi; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

Review 2.  Update on pathophysiology and treatment of hypertension in the elderly.

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2011-10       Impact factor: 5.369

3.  How lifespan associated genes modulate aging changes: lessons from analysis of longitudinal data.

Authors:  Anatoliy I Yashin; Konstantin G Arbeev; Deqing Wu; Liubov S Arbeeva; Alexander Kulminski; Igor Akushevich; Irina Culminskaya; Eric Stallard; Svetlana V Ukraintseva
Journal:  Front Genet       Date:  2013-01-22       Impact factor: 4.599

Review 4.  Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people.

Authors:  Constantine Tsigos; Rafael Bitzur; Yosef Kleinman; Hofit Cohen; Avivit Cahn; Gianmaria Brambilla; Giuseppe Mancia; Guido Grassi
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

5.  Pulse blood pressure and cardiovascular mortality in a population-based cohort of elderly Costa Ricans.

Authors:  L Rosero-Bixby; F Coto-Yglesias; W H Dow
Journal:  J Hum Hypertens       Date:  2015-12-17       Impact factor: 3.012

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.